[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,442
Citations 0
Invited Commentary
June 2015

Osteoporosis Treatment and Fracture Outcomes

Author Affiliations
  • 1Department of Internal Medicine, Helen Hayes Hospital, West Haverstraw, New York
  • 2Department of Medicine, Columbia University, New York, New York
JAMA Intern Med. 2015;175(6):921-922. doi:10.1001/jamainternmed.2015.0757

In this issue of JAMA Internal Medicine, Greenspan and colleagues1 present intriguing data on zoledronic acid, one of the most potent drugs in the bisphosphonate family—if not the most potent—approved for treatment of osteoporosis. In a study of frail elderly women living in nursing homes, the authors suggest that a single 5-mg infusion of zoledronic acid, while producing the expected effects on surrogate outcomes (reducing bone remodeling and increasing bone mineral density [BMD]), failed to reduce the incidence of fractures over a 2-year period. The study deserves careful evaluation and interpretation before any modifications to clinical practice can be recommended.

First Page Preview View Large
First page PDF preview
First page PDF preview